The treatment of infections caused by resistant microorganisms is limited, and vancomycin (VAN) treatment failures for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia are not uncommon, even when MRSA clinical isolates are susceptible to VAN. Thus, this study proposed the association of VAN with usnic acid and β-lapachone encapsulated into liposomes as a novel therapeutic option for infections caused by MRSA. Liposomes containing β-lap (β-lap-lipo) or usnic acid (UA-lipo) were prepared by the thin lipid film hydration method followed by sonication. Antimicrobial activity against MRSA clinical isolates was investigated by the microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). The interaction studies were carried out using the checkerboard method and epsilometer test (Etest). The interaction between VAN and β-lap or β-lap-lipo was synergistic (FICI = 0.453 and FICI = 0.358, respectively). An additive interaction between VAN and UA (FICI = 0.515) was found. UA-lipo resulted in synergism with VAN (FICI = 0.276). The Etest reproduced the results obtained by the checkerboard method for approximately 82% of the analysis. Thus, the present study demonstrated that VAN in combination with UA-lipo, β-lap or β-lap-lipo synergistically enhanced antibacterial activity against MRSA.
INTRODUCTION
The emergence worldwide of multiresistant bacteria has limited conventional antimicrobial therapy and raises serious concerns for public health care systems. From this perspective, methicillin-resistant Staphylococcus aureus (MRSA) is highly virulent and infections caused by MRSA may lead to morbidity and mortality (Zecconi, Scali, 2013) . Consequently, the scientific community is engaged in the development of novel antimicrobial agents, including combination therapy of antimicrobials and/or encapsulated molecules in drug delivery systems (Pinto-Alphandary, Andremont, Couvreur, 2000; Segatore et al., 2012) .
In this scenario, the association of antimicrobial agents for the treatment of infections caused by multiresistant bacteria seems to be significant, since combined therapy may prevent the emergence of resistant isolates and also increase the spectrum of action of antimicrobials due to a synergic effect (Jackson, Agboke, Nwoke, 2009; Silva, Mesquita, Ximenes, 2009; Worthington, Melander, 2013) . Vancomycin (VAN) is the reference drug for the treatment of MRSA; however, MRSA strains have presented vancomycin resistance in vivo even when the in vitro profile was intermediate or susceptible for this drug (Moise et al., 2007; Casapao et al., 2015) .
Furthermore, new compounds of natural origin that exhibit antimicrobial activity have been discovered. Therefore, usnic acid (UA), a secondary lichen metabolite, and β-lapachone (β-lap), a naphthoquinone derived from lapachol extracted from Tabebuia avellanedae bark have been studied to establish their antimicrobial activity (Lauterwein et al., 1995; Lira et al., 2009; Macedo et al., 2013) . Although these molecules exhibit proven antimicrobial activity, they have limitations, such as low water solubility and toxicity, which need to be overcome (Kristmundsdoóttir et al., 2002; Nasongkla et al., 2003; Han et al., 2004) .
Nanostructured systems, such as liposomes, have great appeal as a means of delivery of antibiotics to treat infections. The encapsulation of antibiotics into liposomes offers several advantages, including improvement in their therapeutic efficacy and reduction in toxicity (DrulisKawa, Dorotkiewicz-Jach, 2010; Huh, Kwon, 2011) . Moreover, nanocarriers containing antibiotics can deliver drugs to pathogenic bacteria, while avoiding killing commensal bacteria of the body, regulating the therapy of infections (Abed, Couvreur, 2014) .
Taking into account all these findings, the combination of vancomycin with potential compounds of natural origin alone or encapsulated into nanosystems represents an option to improve the therapeutic index of vancomycin and overcome resistance to this antimicrobial agent. Thus, the aim of this study was to evaluate the in vitro interactions between vancomycin and usnic acid or β-lapachone encapsulated into liposomes against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.
MATERIAL AND METHODS

Material
Vancomycin hydrochloride (VAN) was furnished by ABL -Antibióticos do Brasil (Cosmópolis, São Paulo, Brazil). Usnic acid (UA), cholesterol (Chol) and stearylamine (SA) were purchased from Sigma-Aldrich (St. Louis, USA). Soybean phosphatidylcholine (PC) (98% Epikuron 200 ® ) was obtained from Lipoid GMBH (Ludwigshafen, Germany). Solvents and other chemicals were supplied by Merck (Darmstadt, Germany). Etest strips with vancomycin were purchased from Oxoid (Hampshire, United Kingdom). β-lapachone (β-lap), obtained from lapachol by a semi-synthetic route, was supplied by Dr. Góes (Department of Antibiotics, UFPE, Brazil). Bacterial culture media were purchased from HiMedia (Mumbai, India).
Methods
Preparation of liposomes
Liposomes containing β-lapachone (β-lap-lipo) or usnic acid (UA-lipo) were prepared according to Cavalcanti et al. (2011) and Lira et al. (2009) , respectively, for comparative purposes in the antimicrobial activity evaluation and for the interaction assays with VAN. The liposomal formulations were prepared using the thin lipid film method followed by sonication. Briefly, lipids (PC, Chol and SA) and drugs (β-lap or UA) were dissolved in a mixture of CHCl 3 :CH 3 OH (3:1, v/v) under magnetic stirring. The solvents were then removed under pressure for 60 min (37±1°C, 80 rpm), resulting in a thin lipid film. This film was then hydrated with phosphate buffer solution (pH 7.4). Multilamellar liposomes were then sonicated (Vibra Cell; Branson Ultrasonic, Danbury, CT) at 200 W and 40 Hz for 300 s to form small unilamellar vesicles. The liposomes were characterized by measuring pH, particle size, polydispersion index (PDI), zeta potential and encapsulation efficiency (%EE), as previously described by Cavalcanti et al. (2011) and Lira et al. (2009) .
In vitro antimicrobial activity
Bacterial strains
Staphylococcus aureus clinical isolates (10 strains) were furnished by the hospital of the Federal University of Pernambuco (UFPE, Recife, Brazil) and preserved in the Microbiology and Immunology Laboratory (CAV-UFPE, Brazil). These strains were previously identified as MRSA using the disk diffusion method with cefoxitin and oxacillin as reference drugs, as well as by screening using Müeller-Hinton agar supplemented with 4% NaCl and 6 µg/mL of oxacillin according to the Clinical and Laboratory Standards Institute (CLSI, 2014) (LMB 01, LMB 02, LMB 03, LMB 04, LMB 06, LMB 07, LMB 08, LMB 11, LMB 12 and LMB 13). MRSA ATCC 33591 was used as the control.
Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC)
The in vitro antimicrobial activity of VAN, UA and UA-lipo was evaluated by the microdilution method according to CLSI (2014) . The antimicrobial activity of β-lap and β-lap-lipo against these MRSA clinical isolates has been previously reported by our research group (Cavalcanti et al., 2015) . However their interactions with vancomycin have not yet been investigated.
Interaction assays
Checkerboard method
The in vitro interactions between VAN and UA, UA-lipo, β-lap or β-lap-lipo were evaluated using the checkerboard method . After the determination of MIC, the five MRSA clinical isolates most resistant to VAN were selected for this analysis. Initially, the 96-well microplates were seeded by dispersing Müeller Hinton broth into each well. Subsequently, serially diluted VAN was dispensed on the X-axis of the 96-well microdilution plates and the test drugs (UA, UA-lipo, β-lap or β-lap-lipo) on the Y-axis, to obtain a final concentration equal to the MIC or dilutions lower than the MIC of the respective drugs. Finally, each plate received the adjusted bacterial suspension (10 5 CFU/ mL) and the plates were then incubated at 35 °C for 24 h.
The data were interpreted after calculating the Fractional Inhibitory Concentration Index (FICI) as follows:
where MIC AB equals the MIC of drug A in combination with drug B, MIC A is the MIC of drug A alone, MIC BA equals the MIC of drug B in combination with drug A and MIC B is the MIC of drug B alone. The interaction is considered synergic for FICI ≤0.5; additive for 0.5<FICI≤1, indifferent for 1<FICI≤2 and antagonistic for FICI>2 . The checkerboard assays were also carried out in triplicate.
Etest
The in vitro interactions between VAN and UA, UA-lipo, β-lap or β-lap-lipo were also evaluated by an epsilometer test (Etest) (Sopirala et al., 2010) . The Etest was performed with subinhibitory concentrations of active substances B (UA, UA-lipo, β-lap and β-lap-lipo) of ¼ to ½ of the respective MIC. The same clinical isolates used in the checkerboard test were adjusted at an optical density of 0.5 McFarland units. They were then seeded onto plates and the VAN Etest strips applied to inoculate Müeller-Hinton agar plates containing UA, UA-lipo, β-lap or β-lap-lipo, as well as plates without active substances (control). The plates were then incubated at 35 °C for 24 h.
The results were interpreted as follows: indifferent effect if the MIC of VAN changed within a 1-fold dilution in the respective plate; an additive effect for a reduction of 2-fold dilutions; and synergic effect for 3-fold dilutions according to the manufacturer's recommendations (Etest application sheet EAS 021). All the experiments were performed in triplicate.
Statistical analysis
To compare the data of the in vitro interaction assay, one-way analysis of variance (ANOVA) was applied using the Tukey multiple comparison procedure. The statistical data were considered significant at p < 0.05.
RESULTS
Characterization of liposomes
β-lap-lipo and UA-lipo had a pH of 7.6 and 7.5, particle size of 110.4 ± 0.7 nm and 121.3 ± 1.8 nm, PDI of 0.319 and 0.362, zeta potential of + 22.4 ± 1.8 mV and +11.8 ± 0.5 mV, and %EE of 97.4 ± 1.1% and 99.0 ± 2.7%, respectively.
In vitro antimicrobial activity
The MIC and MBC values of VAN, UA and UA-lipo against MRSA clinical isolates are shown in Table I . As expected, the MIC values of VAN were between 0.25 and 2 µg/mL. The MIC values of UA and UA-lipo ranged from 8 to 32 µg/mL and 4 to 8 µg/mL, respectively.
In vitro interaction assays
Checkerboard method
FICI values obtained in the interaction assays of VAN with UA, UA-lipo, β-lap or β-lap-lipo against MRSA clinical isolates are depicted in Figure 1 . With regard to the interaction of VAN with UA, an additive interaction for almost all the MRSA clinical isolates was evident (FICI = 0.51), except for LMB 03, which exhibited synergic interactions (FICI = 0.26). The UA-lipo/VAN association had a synergic effect on all the MRSA clinical isolates tested (FICI = 0.25-0.30). Statistically significant differences between the interactions of UA/VAN and UAlipo/VAN were found.
With regard to the in vitro interaction between VAN and β-lap, synergism was found and the profile remained unaltered when β-lap was encapsulated into liposomes (FICI = 0.26-0.50), whereas the predominant FICI for other combinations involving these two compounds was 0.5 (Figure 1 ). The statistical analysis showed significant differences between the interactions of β-lap/VAN and β-lap-lipo/VAN.
Moreover, there were no statistically significant differences between the interactions of β-lap-lipo/VAN and UA-lipo/VAN, suggesting that the encapsulation of drugs into liposomes associated with VAN represents a promising therapy against MRSA.
Etest
The results of the interactions of VAN with UA, UA-lipo, β-lap or β-lap-lipo against MRSA clinical isolates using the Etest are listed in Table II . The data obtained using the Etest confirmed the results found with the checkerboard method in 82.5% of the analysis. Only seven of the forty combinations were not consistent with the other method (17.5%). The discordant combinations were VAN/ ½ MIC UA-lipo for LMB 08; VAN/ ¼ MIC UA-lipo for LMB 01 and LMB 08; VAN/ ½ and ¼ MIC β-lap for LMB 08, as well as VAN/ ¼ MIC β-lap-lipo for LMB 01 and LMB 06.
DISCUSSION
The liposomal formulations exhibited suitable physicochemical characteristics, such as particle size, PDI, zeta potential and pH, for future in vivo therapeutic applications (Pinto-Alphandary, Andremont, Couvreur, 2000) . Since the administration route of these nanocarriers is intravenous, formulations must have a pH within the range of neutrality, particle size of below 200 nm and PDI below 1 to prevent harmful effects on patients, such as acid-base disorders or vessel obstruction (Hinrichs et al., 2006; Elsabahy, Wooley, 2012) . In addition, the positive surface charge of the liposomes is important for their electrostatic attraction with the negative cell wall of bacteria (Xia, Kohler, Peschel, 2010) . Finally, the high encapsulation rate of AU and β-lap in liposomes demonstrated the efficiency of the encapsulation method used in this study.
Regarding the susceptibility of MRSA clinical isolates to VAN, the CLSI (2014) (Moise et al., 2007; Lodise et al., 2008; Casapao et al., 2015) .
The MIC values of UA against MRSA were consistent with data on UA antimicrobial activity previously reported in the literature. In 1995, Lauterwein et al. found usnic acid MICs in the 8 to 16 µg/mL range against MRSA clinical isolates.
UA-lipo had heightened bacteriostatic activity when compared with pure UA, showing a decrease in MIC from 8-32 µg/mL to 4-8 µg/mL. One explanation for the improvement in antimicrobial activity produced by the encapsulation of UA into liposomes is the possible fusion of the nanostructured systems with the cell wall of S. aureus, which allows an increased amount of active substance within the bacterial cells. In fact, UA is able to cross biological membranes by modulating its solubility through protonation/deprotonation of 3-OH in a physiological pH environment (Sharma, Jannke, 1996) . As recently reported for in silico simulation studies, UA, in its usnate ionic form, causes perturbation in phospholipid bilayers, which undergo a lamellar to nonlamellar transition phase (Nadvorny, Da Silva, Lins, 2014) .
In the interaction study by the checkerboard method, the encapsulation of UA into liposomes appeared to be a promoter factor for synergism. The combination therapy of VAN with other antibiotics has clearly emerged as a potential approach to overcome the decrease in bacterial susceptibility to this reference drug. Our findings thus suggest UA, especially encapsulated into liposomes, as a possible promoter to improve VAN antimicrobial activity and proved more significant than results obtained by Segatore et al. (2012) . The cited authors analyzed the interaction of UA with five antibiotics used in clinical therapy (clindamycin, erythromycin, gentamicin, oxacillin and levofloxacin) against four MRSA clinical isolates. For all isolates studied, the interaction of UA with erythromycin, oxacillin and levofloxacin was indifferent; for clindamycin, the interaction with UA was synergic for only one isolate, yet indifferent for the other three. Synergic interactions of UA with gentamicin were found for two of the four strains and indifferent interaction for the other two.
The results for β-lap interactions with VAN are in agreement with those of Macedo et al. (2013) for interactions between β-lap and ampicillin, amoxicillin/ clavulanic acid, cefoxitin, ciprofloxacin or meropenem against five MRSA isolates. A synergism in almost all interactions between β-lap and antibiotics tested (FICIs = 0.346, 0.166, 0.375, 0.384 and 0.224, respectively) was observed, except for the additive interaction between β-lap and ciprofloxacin against one isolate (FICI = 0.56).
In the past few decades, in vitro synergistic interactions of VAN with antimicrobial agents for antibacterial therapy have been reported. You et al. (2000) investigated the existence of synergism between arbekacin and VAN and compared it with the in vitro interaction of the classical combination of gentamicin and VAN against MRSA isolates resistant to gentamicin. The arbekacin/VAN combination exhibited a synergic effect against twelve of the thirteen isolates tested, whereas the gentamicin/VAN combination was synergistic for only seven.
Some of the combinations assessed in our study (UA-lipo/VAN, β-lap/VAN and β-lap-lipo/VAN) seem to be more synergistic than the standard combination (gentamicin/VAN), as the combinations were synergistic in 100% of the MRSA isolates tested. In 2010, Mahboubi and Bidgoli also evaluated the in vitro interaction of vancomycin with natural products, such as Zataria multiflora essential oil, against MRSA clinical isolates. Similar to our results, the interaction was synergistic between these substances (FICI = 0.32).
The level of agreement between the data from the Etest and the checkerboard methods was notable (82.5%) and comparable with previous studies (White et al., 1996; Sopirala et al., 2010) . White et al. (1996) investigated the interaction between antibiotics against gram positive and gram negative bacteria using the Etest and checkerboard methods and observed a greater discrepancy of approximately 25%. Sopirala et al. (2010) analyzed the interaction between antibiotics against PanDrug-Resistant Acinetobacter baumannii and found a discrepancy of around 15% between the results obtained from the two tests in question.
Thus, the results observed in the checkerboard method corroborate the Etest observation performed in our study and these microbial experiments suggested that VAN combined with UA-lipo, β-lap or β-lap-lipo synergistically enhanced its antibacterial activity against methicillinresistant Staphylococcus aureus clinical isolates.
CONCLUSION
Vancomycin exhibited synergism with UA and β-lap encapsulated into liposomal formulations. Therefore, these natural compounds encapsulated into the drug delivery system may be a potential therapeutic approach for improving the antimicrobial activity of vancomycin in the treatment of MRSA. Further studies in animal models are needed to evaluate the in vivo antimicrobial effect of these combinations and their potential use in the treatment of infections caused by MRSA.
